Canadian Medical Association Journal, Vol 152, Issue 3 351-357, Copyright © 1995 by Canadian Medical Association
JOURNAL ARTICLE |
Basic statistics for clinicians: 3. Assessing the effects of treatment: measures of association
R. Jaeschke, G. Guyatt, H. Shannon, S. Walter, D. Cook and N. Heddle
Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ont.
In the third of a series of four articles the authors show the calculation of measures of association and discuss their usefulness in clinical decision making. From the rates of death or other "events" in experimental and control groups in a clinical trial, we can calculate the relative risk (RR) of the event after the experimental treatment, expressed as a percentage of the risk without such treatment. The absolute risk reduction (ARR) is the difference in the risk of an event between the groups. The relative risk reduction is the percentage of the baseline risk (the risk of an event in the control patients) removed as a result of therapy. The odds ratio (OR), which is the measure of choice in case-control studies, gives the ratio of the odds of an event in the experimental group to those in the control group. The OR and the RR provide limited information in reporting the results of prospective trials because they do not reflect changes in the baseline risk. The ARR and the number needed to treat, which tells the clinician how many patients need to be treated to prevent one event, reflect both the baseline risk and the relative risk reduction. If the timing of events is important--to determine whether treatment extends life, for example--survival curves are used to show when events occur over time.
This article has been cited by other articles:
 |
|
 |
|
  M. J. Ferrill, D. A. Brown, and J. A. Kyle Clinical Versus Statistical Significance: Interpreting P Values and Confidence Intervals Related to Measures of Association to Guide Decision Making Journal of Pharmacy Practice, August 1, 2010; 23(4): 344 - 351. [Abstract] [PDF]
|
|
|
|
 |
|
 J. P A Ioannidis, N. A Patsopoulos, and H. R Rothstein Reasons or excuses for avoiding meta-analysis in forest plots BMJ, June 21, 2008; 336(7658): 1413 - 1415. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Nexoe, D. Gyrd-Hansen, J. Kragstrup, I. S. Kristiansen, and J. B. Nielsen Danish GPs' perception of disease risk and benefit of prevention Fam. Pract., February 1, 2002; 19(1): 3 - 6. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. van Nieuwenhoven, E. Buskens, F. H. van Tiel, and M. J. M. Bonten Relationship Between Methodological Trial Quality and the Effects of Selective Digestive Decontamination on Pneumonia and Mortality in Critically Ill Patients JAMA, July 18, 2001; 286(3): 335 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. M. Bonten, B. J. Kullberg, R. van Dalen, A. R. J. Girbes, I. M. Hoepelman, W. Hustinx, J. W. M. van der Meer, P. Speelman, E. E. Stobberingh, H. A. Verbrugh, et al. Selective digestive decontamination in patients in intensive care J. Antimicrob. Chemother., September 1, 2000; 46(3): 351 - 362. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Guell, P. Casan, J. Belda, M. Sangenis, F. Morante, G. H. Guyatt, and J. Sanchis Long-term Effects of Outpatient Rehabilitation of COPD: A Randomized Trial Chest, April 1, 2000; 117(4): 976 - 983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Guyatt A 75-Year-Old Man With Congestive Heart Failure JAMA, June 23, 1999; 281(24): 2321 - 2328. [Full Text] [PDF]
|
|
|
|
|
|
G. H Guyatt, E. F Juniper, S. D Walter, L. E Griffith, and R. S Goldstein Interpreting treatment effects in randomised trials BMJ, February 28, 1998; 316(7132): 690 - 693. [Full Text]
|
|
|
|
|
|
G. H. Guyatt, D. L. Sackett, J. C. Sinclair, R. Hayward, D. J. Cook, R. J. Cook, Evidence-Based Medicine Working Group, E. Bass, H. Gerstein, B. Haynes, et al. Users' Guides to the Medical Literature: IX. A Method for Grading Health Care Recommendations JAMA, December 13, 1995; 274(22): 1800 - 1804. [Abstract] [PDF]
|
|